US-based Azurity Pharmaceuticals Inc announced on Tuesday that the US Food and Drug Administration (FDA) has approved XIFYRM (meloxicam injection), an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. XIFYRM provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds. Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required.
"XIFYRM demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," commented Ron Scarboro, Azurity Pharmaceuticals CEO. "XIFYRM addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies."
Azurity Pharmaceuticals expects XIFYRM to be available in the coming weeks.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid